An Evidence-based Review for the NIH Consensus Development Conference on Hydroxyurea for the Treatment of Adults with Sickle Cell Disease

Established in 1927 by the American College of Physicians

Abstract/Editors' Note | Full Text

FIGURES/TABLES SUMMARY PAGE

PowerPoint slides are available for most Figures at Annals.org

An Evidence-Based Review for the NIH Consensus Development Conference on Hydroxyurea for the Treatment of Adults with Sickle Cell Disease

View larger version (61K):
[in this window]
[in a new window]

Figure 1. Study flow diagram.

*The evidence report provides details of the search strategies (7). ${dagger}$ The reasons for exclusion exceed the total number of studies because reviewers could enter multiple reasons for exclusion. ${ddagger}$ 89 studies were not included in this review because they included children or infants only or examined barriers only. Toxicity and efficacy studies in sickle cell disease overlap.

View this table:
[in this window]
[in a new window]

Table 1. Characteristics of RCTs and Observational Studies of Hydroxyurea for Treatment of Sickle Cell Disease*

View this table:
[in this window]
[in a new window]

Table 2. Outcomes of RCTs and Observational Studies of Hydroxyurea for Treatment of Sickle Cell Disease*

View this table:
[in this window]
[in a new window]

Table 3. Toxicity Results in Studies of Hydroxyurea for Sickle Cell Disease*

View this table:
[in this window]
[in a new window]

Table 4. Summary of the Evidence in Sickle Cell Disease*